Friday, 20 Oct 2017

You are here

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. FDA has announced Arthritis Advisory Hearing on Aug 2nd (Sirukumab in RA) and Aug 3rd (Tofacitinib in PsA) http://buff.ly/2uiBRM7
  2. Metanalyses suggest a decreasing risk of CVD in rheumatoid arthritis after 2000 http://buff.ly/2vgC3Zu
  3. Monitoring IgG4 related disease w/ ESR CRP IgG4 levels not reliable. but imaging w/ 18F-FDG PET/CT reflects activity http://buff.ly/2tiFk9132
  4. SLE nephritis & 64 controls show pregnancy on lupus nephritis does not increase SLE flares, renal outcomes or CKD https://t.co/gK1lzJTZc9
  5. NEJM Study >73K shows Improved diet quality over 12 yrs associated w/ decreased risk of death (7-17% less mortality) https://t.co/2MOTfTiFPs
  6. Baricitinib gets market approval in Japan (https://t.co/9c0JmNMWjq) & NICE recommends Oluminant for UK approval (https://t.co/2Zchi0Kev3)
  7. IOM review shows uninsured have poorer health & shortened lives;Concludes health insurance reduces the risk of death https://t.co/0ndNNGzIoV
  8. Warnings section of the OTEZLA (apremilast) label updated to include risk of severe diarrhea, nausea, and vomiting. https://t.co/ljdKlcUlPbRT
  9. Population study of 40K Dutch finds ACPA positivity in 1%; assoc w/ age, smoking, female & RA;but only 15-20% had RA https://t.co/96DvKWPYTL
  10. increased pregnancy-induced type I IFN-inducible gene expression observed in preg RA women who improved during preg https://t.co/VwFrpH18YGRT
  11. Orencia Approved for Use in Psoriatic Arthritis  
  12. Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture
  13. Withdrawal of TNF Inibitors Fails in Most RA Patients
  14. Statins Improve Survival in Ankylosing Spondylitis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Jack-I may have mentioned this in the past but again wonder if the improvement of CVD in RA patients may be a result of the markedly decreased use of NSAIDs as background therapy in RA patients on cDMARDs and bDMARDs since 2000.-D,Knapp
I think yours is a very valid point as research has shown a definite decline in NSAID use after the VIOXX/Cox-2 FDA hearing. But are rheums using more low dose prednisone instead? Researchers should control for these issues in their analyses. Good Point! JC

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.